United Therapeutics (NASDAQ:UTHR) CEO Sells $5,268,795.00 in Stock

United Therapeutics Corporation (NASDAQ:UTHR) CEO Martine Rothblatt sold 9,500 shares of the company’s stock in a transaction on Thursday, July 2nd. The stock was sold at an average price of $554.61, for a total transaction of $5,268,795.00. Following the sale, the chief executive officer directly owned 40,513 shares of the company’s stock, valued at approximately $22,468,914.93. This represents a 19.00% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this link.

United Therapeutics Price Performance

Shares of UTHR opened at $555.91 on Friday. The company has a market capitalization of $23.60 billion, a PE ratio of 20.52, a price-to-earnings-growth ratio of 1.82 and a beta of 0.58. United Therapeutics Corporation has a one year low of $272.12 and a one year high of $609.35. The company’s fifty day moving average price is $558.34 and its 200 day moving average price is $527.84.

United Therapeutics (NASDAQ:UTHR) last issued its quarterly earnings results on Wednesday, May 6th. The biotechnology company reported $5.82 earnings per share (EPS) for the quarter, missing the consensus estimate of $7.00 by ($1.18). The business had revenue of $781.50 million during the quarter, compared to analyst estimates of $797.40 million. United Therapeutics had a net margin of 40.62% and a return on equity of 19.24%. The company’s revenue for the quarter was down 1.6% compared to the same quarter last year. During the same period in the prior year, the business posted $6.63 earnings per share. Analysts anticipate that United Therapeutics Corporation will post 26.63 earnings per share for the current year.

More United Therapeutics News

Here are the key news stories impacting United Therapeutics this week:

• Positive Sentiment: United Therapeutics agreed to acquire Thymmune Therapeutics for $140 million upfront, with up to $160 million in milestone payments. The deal adds Thymmune’s preclinical thymic cell therapy THY-100 and expands UTHR’s regenerative medicine platform, especially for organ transplantation tolerance and related immune disorders. Article Title
• Positive Sentiment: Analysts continue to view UTHR favorably overall, with the stock carrying a Moderate Buy consensus rating. That suggests the market still sees upside support despite recent volatility and insider sales. Article Title
• Neutral Sentiment: CEO Martine A. Rothblatt and EVP Paul Mahon both sold shares this week, which can create a modest overhang for investor sentiment, though these sales were disclosed and do not necessarily signal a change in the company’s fundamentals. Article Title
• Neutral Sentiment: United Therapeutics recently reported quarterly results that missed analyst expectations on both earnings and revenue, so investors may still be weighing the company’s strong long-term growth strategy against softer near-term execution. Article Title

Institutional Trading of United Therapeutics

A number of institutional investors and hedge funds have recently modified their holdings of UTHR. Geneos Wealth Management Inc. boosted its stake in United Therapeutics by 141.7% during the first quarter. Geneos Wealth Management Inc. now owns 145 shares of the biotechnology company’s stock worth $45,000 after buying an additional 85 shares in the last quarter. Northwestern Mutual Wealth Management Co. raised its stake in shares of United Therapeutics by 18.8% in the 2nd quarter. Northwestern Mutual Wealth Management Co. now owns 443 shares of the biotechnology company’s stock valued at $127,000 after buying an additional 70 shares in the last quarter. Jump Financial LLC bought a new position in shares of United Therapeutics during the 2nd quarter worth about $277,000. Cerity Partners LLC lifted its holdings in shares of United Therapeutics by 77.3% during the 2nd quarter. Cerity Partners LLC now owns 12,843 shares of the biotechnology company’s stock worth $3,691,000 after acquiring an additional 5,600 shares during the period. Finally, Bank of Nova Scotia boosted its position in shares of United Therapeutics by 6.9% during the 2nd quarter. Bank of Nova Scotia now owns 1,628 shares of the biotechnology company’s stock valued at $468,000 after acquiring an additional 105 shares in the last quarter. 94.08% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

Several brokerages have commented on UTHR. Weiss Ratings reaffirmed a “buy (b)” rating on shares of United Therapeutics in a research report on Thursday, June 11th. TD Cowen restated a “buy” rating on shares of United Therapeutics in a research note on Thursday, May 21st. Raymond James Financial initiated coverage on shares of United Therapeutics in a research report on Friday, April 10th. They set an “outperform” rating and a $700.00 target price on the stock. HC Wainwright increased their price target on shares of United Therapeutics from $600.00 to $660.00 and gave the company a “buy” rating in a report on Tuesday, March 31st. Finally, Wells Fargo & Company raised shares of United Therapeutics from an “equal weight” rating to an “overweight” rating and increased their price target for the company from $575.00 to $735.00 in a report on Thursday, May 7th. Eleven equities research analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company. Based on data from MarketBeat, United Therapeutics presently has a consensus rating of “Moderate Buy” and an average target price of $619.42.

About United Therapeutics

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.